argenex SE $ARGX Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC trimmed its position in shares of argenex SE (NASDAQ:ARGX) by 4.5% in the fourth quarter, Holdings Channel.com reports. The firm owned 2,458,164 shares of the company’s stock after selling 117,087 shares during the period. argenex comprises approximately 0.9% of Janus Henderson Group PLC’s investment portfolio, making the stock its 13th largest position. Janus Henderson Group PLC’s holdings in argenex were worth $2,057,856,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Capital World Investors grew its holdings in argenex by 0.4% during the 3rd quarter. Capital World Investors now owns 1,959,504 shares of the company’s stock valued at $1,445,113,000 after purchasing an additional 8,422 shares in the last quarter. M&T Bank Corp grew its holdings in argenex by 20,977.7% during the 4th quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock valued at $654,772,000 after purchasing an additional 774,916 shares in the last quarter. Wellington Management Group LLP grew its holdings in argenex by 80.1% during the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock valued at $538,408,000 after purchasing an additional 324,653 shares in the last quarter. Morgan Stanley grew its holdings in argenex by 19.2% during the 4th quarter. Morgan Stanley now owns 518,852 shares of the company’s stock valued at $436,331,000 after purchasing an additional 83,746 shares in the last quarter. Finally, Sands Capital Management LLC grew its holdings in argenex by 2,046.6% during the 4th quarter. Sands Capital Management LLC now owns 356,870 shares of the company’s stock valued at $300,110,000 after purchasing an additional 340,245 shares in the last quarter. 60.32% of the stock is owned by institutional investors and hedge funds.

argenex Price Performance

Shares of ARGX stock opened at $892.26 on Thursday. The firm has a market cap of $55.49 billion, a P/E ratio of 39.73, a P/E/G ratio of 1.34 and a beta of 0.47. argenex SE has a 1-year low of $510.05 and a 1-year high of $934.62. The firm has a fifty day moving average of $820.36 and a two-hundred day moving average of $810.81.

argenex (NASDAQ:ARGX) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share (EPS) for the quarter. argenex had a net margin of 31.31% and a return on equity of 44.37%. The company had revenue of $1.31 billion for the quarter. On average, sell-side analysts expect that argenex SE will post 26.19 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ARGX. Guggenheim raised their price objective on shares of argenex from $1,120.00 to $1,135.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Robert W. Baird raised their price objective on shares of argenex from $858.00 to $867.00 and gave the stock a “neutral” rating in a report on Friday, February 27th. Wedbush reissued an “outperform” rating and set a $1,000.00 price objective on shares of argenex in a report on Thursday, June 11th. HC Wainwright raised their price objective on shares of argenex from $915.00 to $940.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Finally, Zacks Research raised shares of argenex from a “strong sell” rating to a “hold” rating in a report on Friday, February 20th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,019.50.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.